1. Introduction
===============

The development of a malignantly transformed cell from a normal cell is a complex multi-step process that remains incompletely understood \[[@B1-cancers-04-01180],[@B2-cancers-04-01180]\]. "Bottom-up" studies of relevant processes such as control of cell division, cell migration, tissue remodeling, and cell death have allowed the identification and characterization of many individual genes whose malfunction due to mutation or misregulation is associated with malignant transformation \[[@B3-cancers-04-01180],[@B4-cancers-04-01180],[@B5-cancers-04-01180],[@B6-cancers-04-01180]\]. More recently, the development of high-throughput studies that exploit the availability of whole-genome sequencing has enabled "top-down" studies to systematically catalogue somatically mutated genes and altered patterns of gene expression in individual tumors \[[@B7-cancers-04-01180],[@B8-cancers-04-01180]\]. These studies have confirmed the importance of genes identified as key players in the "bottom-up" studies, but have also suggested roles for additional genes and gene combinations not previously associated with processes relevant to malignancy.

Pathway databases have been effectively used to annotate our "bottom-up" understanding of molecular details of processes relevant to cell growth, differentiation, migration, and death. Here, we describe one such database, Reactome, focusing on extensions to this basic annotation strategy to allow the capture of details of disease processes, and on the development of data analysis tools to support the annotation and interpretation of gene sets identified in top-down studies.

Reactome is an open-source, open access, curated and peer-reviewed biological knowledgebase of human reactions, pathways and processes that serves as a platform for pathway visualization and analysis \[[@B9-cancers-04-01180],[@B10-cancers-04-01180],[@B11-cancers-04-01180],[@B12-cancers-04-01180]\]. Reactome provides information about proteins and small molecules and how they participate in pathways to coordinate cellular events. The Reactome database employs a reductionist data model, which represents biology as reactions that convert input physical entities into output physical entities. The Reactome definition of a "reaction" is broad, including binding, dissociation, translocation and degradation, in addition to biochemical transformations of proteins and small molecules. Reactions are linked in causal chains to form pathways which in turn are grouped to represent larger biological processes like intermediary metabolism, innate immunity, solute transport, GPCR signal transduction, and apoptosis \[[@B13-cancers-04-01180],[@B14-cancers-04-01180]\].

Reactome curators, in collaboration with outside expert researchers, annotate new pathways. The molecular details of every reaction are traceable to experimental evidence in the primary literature. If an event has not been directly studied in human systems, the appropriate non-human reaction is annotated and the homologous human one is inferred from it. Every pathway module is peer-reviewed by an additional expert. New and revised modules are publicly released to the Reactome website every quarter. Pathways, reactions, protein and small molecule entities are cross referenced with accession numbers and identifiers to a number of well-established databases, including NCBI Gene \[[@B15-cancers-04-01180]\], Ensembl \[[@B16-cancers-04-01180]\] and UniProt databases \[[@B17-cancers-04-01180]\], UCSC Genome Browser \[[@B18-cancers-04-01180]\], and ChEBI \[[@B19-cancers-04-01180]\]. Physical entities and events are further linked to "Molecular Function", "Biological Process" and "Cellular Component" ontology terms found in Gene Ontology (GO) \[[@B20-cancers-04-01180]\].

Currently, the pathways in Reactome cover about 25% of the gene products encoded in the human genome, and contain the normal versions of many pathways that can be abnormally activated in cancer, such as "Signaling by EGFR" \[[@B21-cancers-04-01180]\], "Signaling by FGFR" \[[@B22-cancers-04-01180]\], "Signaling by NOTCH" \[[@B23-cancers-04-01180]\], "PIP3 Activates AKT Signaling" \[[@B24-cancers-04-01180]\], "RAF/MAP Kinase Cascade" \[[@B25-cancers-04-01180]\]. We have also annotated a number of pathways that can be inactivated in cancer, such as pathways involving TP53: "Apoptosis" \[[@B26-cancers-04-01180]\] and "Cell Cycle Checkpoints" \[[@B27-cancers-04-01180]\], as well as pathways involving the RB1 protein family: "Mitotic G1-G1/S phases" \[[@B28-cancers-04-01180]\].

Here, we use the epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) and PI3K/AKT signaling pathways to illustrate Reactome annotation of cancer pathways. EGFR and FGFR are transmembrane receptor tyrosine kinases. EGFR is activated by several growth factors, including the epidermal growth factor (EGF) \[[@B29-cancers-04-01180]\]. FGFR family members (FGFR1, FGFR2, FGFR3 and FGFR4) are activated by 18 of 22 existing human fibroblast growth factors (FGFs), with each FGFR showing different affinity for individual FGFs \[[@B30-cancers-04-01180]\]. Growth factor binding induces a conformational change that enables dimerization and trans-autophosphorylation on C-tail tyrosine residues of EGFR \[[@B31-cancers-04-01180]\] and FGFRs \[[@B32-cancers-04-01180],[@B33-cancers-04-01180],[@B34-cancers-04-01180]\]. Phosphorylated tyrosines in the C-tails of EGFR and FGFR serve as docking sites for downstream effectors that, upon binding to phosphorylated receptors, activate intracellular signaling cascades that regulate cellular proliferation, differentiation, and survival \[[@B30-cancers-04-01180],[@B35-cancers-04-01180],[@B36-cancers-04-01180]\]. One of the intracellular signaling cascades downstream of EGFR and FGFRs is PI3K/AKT signaling \[[@B37-cancers-04-01180],[@B38-cancers-04-01180]\]. PI3K class IA enzymes are heterodimers composed of a regulatory subunit p85 (encoded by PIK3R1, PIK3R2 or PIK3R3) and a catalytic subunit p110 (encoded by PIK3CA, PIK3CB or PIK3CD) \[[@B39-cancers-04-01180]\]. The catalytic p110 subunit of PI3K becomes activated when inhibitory contacts with the p85 regulatory subunit are relieved by p85 binding to phosphorylated adaptor proteins recruited to activated EGFR or FGFRs \[[@B40-cancers-04-01180],[@B41-cancers-04-01180]\]. Active PI3K class I enzymes phosphorylate PIP2 (phosphatidylinositol-4,5-bisphophate), converting it into PIP3 (phosphatidylinositol-3,4,5-trisphosphate), a reaction negatively regulated by PTEN phosphatase \[[@B42-cancers-04-01180]\]. PIP3 serves as a second messenger that activates AKT (AKT1, AKT2 or AKT3) \[[@B43-cancers-04-01180]\]. AKT family members are cytosolic and nuclear serine/threonine protein kinases involved in phosphorylation-mediated regulation of numerous proteins involved in cell survival and growth \[[@B39-cancers-04-01180]\].

EGFR, FGFRs, PIK3CA, PIK3R1 and AKT1 are proto-oncogenes, frequently activated in cancer through gain-of-function mutations and/or overexpression. PTEN is an established tumor suppressor gene, with a frequent loss of function in cancer \[[@B44-cancers-04-01180]\]. Gain-of-function mutations in EGFR \[[@B45-cancers-04-01180],[@B46-cancers-04-01180]\] and FGFRs \[[@B47-cancers-04-01180],[@B48-cancers-04-01180],[@B49-cancers-04-01180],[@B50-cancers-04-01180],[@B51-cancers-04-01180]\] usually act by conferring ligand-independent activation or by increasing tyrosine kinase catalytic activity. Mutations in PIK3R1 or PIK3CA abolish inhibitory interactions between the regulatory and catalytic subunit of PI3K \[[@B52-cancers-04-01180],[@B53-cancers-04-01180],[@B54-cancers-04-01180],[@B55-cancers-04-01180],[@B56-cancers-04-01180]\], resulting in PI3K activity in the absence of growth factor stimulation. AKT1 gain of function mutations increase AKT1 affinity for PIP2, allowing AKT1 activation in the absence of PI3K activity and PIP3 generation \[[@B57-cancers-04-01180]\]. PTEN loss-of-function mutations usually affect the phosphatase domain, impairing PTEN catalytic activity and removal of PIP3 \[[@B58-cancers-04-01180]\].

Small molecule therapeutics and recombinant antibodies are being developed as potential treatments for cancers driven by increased activity of EGFR, FGFR and/or PI3K/AKT. Gefitinib and erlotinib, small tyrosine kinase inhibitors, are approved for the clinical treatment of cancers harboring specific EGFR mutations. A recombinant antibody, cetuximab, is approved for the clinical treatment of cancers that overexpress wild-type EGFR \[[@B59-cancers-04-01180]\]. Small molecules that inhibit the catalytic activity of FGFRs \[[@B60-cancers-04-01180]\], PI3K and AKT \[[@B61-cancers-04-01180]\] are currently undergoing clinical trials or are in pre-clinical development.

We have extended the Reactome data model and enhanced the web tools to permit the annotation and visualization of the altered biological behavior of protein variants. These enhancements can be applied to any molecular abnormality due to germline or somatic mutation, as well as to abnormalities due to expression of foreign proteins encoded by genomes of infectious agents like viruses or intracellular parasites.

2. Results and Discussion
=========================

2.1. Annotation of Cancer-Perturbed Pathways
--------------------------------------------

Pathways that stimulate cell growth, cell division and survival, and maintenance of undifferentiated state are activated in cancer through gain-of-function mutations in participating proto-oncogenes and/or their overexpression. On the other hand, pathways that negatively regulate cell division, growth and survival, or promote cellular differentiation are inactivated through loss-of-function mutations in tumor suppressor genes and/or their downregulation. To capture these two groups of cancer effectors, we have added new classes of data to the Reactome database.

### 2.1.1. Extension of Protein Modifications to Accommodate Annotation of Changes in Amino Acid Sequence

The protein modification class in the Reactome data model was constructed to support annotation of covalent co- and post-translational modifications of proteins such as the phosphorylation of serine residues. To allow for annotation of mutant proteins, two new subclasses of modifications were introduced: Replaced Residue and Fragment Modification ([Figure 1](#cancers-04-01180-f001){ref-type="fig"}a). The Replaced Residue class is used to annotate amino acid substitutions in a protein sequence. A Replaced Residue instance associates a specific coordinate of a protein sequence with two PSI-MOD ontology \[[@B62-cancers-04-01180]\] attributes: the first identifies the amino acid found at that position in the normal protein and the second attribute identifies the amino acid that replaces it in the mutant protein. For example, the most frequently found mutation in EGFR is the substitution of a leucine residue at position 858 with an arginine residue in the catalytic domain of EGFR. This mutation disrupts autoinhibitory interactions, facilitating adoption of an active conformation \[[@B63-cancers-04-01180]\]. The Reactome record for EGFR L858R ([Figure 1](#cancers-04-01180-f001){ref-type="fig"}b) indicates this amino acid substitution.

The FragmentModification subclass includes two subclasses, FragmentInsertionModification and FragmentDeletionModification. FragmentInsertionModification is used to annotate insertions of amino acid residues in a protein sequence. FragmentDeletionModification is used to annotate removal of amino acid residues. PIK3R1 Y463_L466del is a variant of the PI3K regulatory subunit p85alpha found in endometrial cancer ([Figure 1](#cancers-04-01180-f001){ref-type="fig"}c). This PIK3R1 mutant lacks four amino acid residues in the inter-SRC homology 2 (iSH2) domain. PIK3R1 is able to bind the catalytic subunit of PI3K, PIK3CA (p110alpha), but does not inhibit it, resulting in the constitutive activity of PI3K, in the absence of growth factors \[[@B64-cancers-04-01180]\]. The deletion coordinates are indicated in the Reactome record for PIK3R1 Y463_L466del mutant.

![Annotation of cancer mutations. Reactome records are not displayed in their entirety due to space limitations. (**a**) Subclasses of protein modifications contained in Reactome class Abstract Modified Residue. Currently, Reactome website displays all subclasses of protein modifications in the single field "Post-translational modification(s)". Future changes to the website will allow chemical modifications to be distinguished from effects of mutations. (**b**) Reactome record for EGFR L858R caused by a missense mutation that replaces leucine residue at position 858 with arginine. (**c**) Reactome record for PIK3R1 Y463_L466del caused by an in-frame intragenic deletion in PIK3R1 that removes amino acid residues from position 463 to position 466, as captured by the Fragment Deletion Modification instance. (**d**) Reactome record for BCR-FGFR1 fusion protein. Truncation of the wild-type BCR protein sequence is shown by altered end coordinate. FGFR1 fragment fused to BCR is annotated as an insertion using FragmentInsertionModification class.](cancers-04-01180-g001){#cancers-04-01180-f001}

The FragmentModification class can also be used to annotate fusion proteins. For example, the translocation t(8;22)(p11;q11) in chronic myeloid leukemia produces a BCR-FGFR1 fusion that consists of the first four exons of BCR and exons 9--18 of FGFR1 \[[@B65-cancers-04-01180]\]. The BCR-FGFR1 fusion protein is annotated as an Entity with Accessioned Sequence ([Figure 1](#cancers-04-01180-f001){ref-type="fig"}d) that consists of a truncated BCR protein, starting at position 1 and ending at position 584 of the reference UniProt sequence P11274 (human BCR). Then, a FragmentInsertionModification instance defines insertion of amino acids 429--822 of the UniProt reference sequence P11362 (human FGFR1) at position 585 of BCR ([Figure 1](#cancers-04-01180-f001){ref-type="fig"}d).

On the Reactome website, selecting a physical entity or an event node by clicking on a pathway diagram brings up a record for that particular instance in the details pane, which appears by clicking on the yellow triangle at the bottom of the Pathway Browser page. Selecting EGFRvIII in the diagram ([Figure 2](#cancers-04-01180-f002){ref-type="fig"}a), brings up Reactome information on this mutant protein, as well as interactive cross references that direct users to other Reactome website pages or other databases of interest ([Figure 2](#cancers-04-01180-f002){ref-type="fig"}b). Each cancer-related disease variant record cross-references available records in the Catalogue of Somatic Mutations in Cancer (COSMIC) database ([Table 1](#cancers-04-01180-t001){ref-type="table"}) \[[@B66-cancers-04-01180]\]. The EGFRvIII record displayed on Reactome website links to COSMIC record 21351, which provides information on nucleotide sequence changes and tumor samples in which this mutation was reported.

### 2.1.2. Associating Disease Attributes with Physical Entities and Events

All physical entities related to disease variants, such as proteins, sets of proteins, and protein complexes are tagged with disease attributes ([Table 1](#cancers-04-01180-t001){ref-type="table"}), using a term from the Disease Ontology (DO) \[[@B67-cancers-04-01180]\]. This DO record provides, when possible, a link to the synonymous disease record in the National Cancer Institute Thesaurus (NCIt) \[[@B68-cancers-04-01180]\]. The disease attribute of the physical entity is assigned to all reactions and pathways in which it participates.

Besides providing information on disease involvement of specific proteins and directing users to more detailed disease descriptions, a disease attribute annotation enables users to search Reactome database for proteins and events associated with a specific disease. For example, in [Figure 2](#cancers-04-01180-f002){ref-type="fig"}b, a DO instance "adult glioblastoma multiforme" is associated with EGFRvIII. Clicking on the "adult glioblastoma multiforme" link displayed on Reactome website ([Figure 2](#cancers-04-01180-f002){ref-type="fig"}b) provides a DO identifier for this disease instance (3075) and also lists all other proteins in Reactome database whose mutant forms are associated with adult glioblastoma multiforme ([Figure 2](#cancers-04-01180-f002){ref-type="fig"}c). Thus, Reactome provides cancer researchers with a quick access to cancer type-specific disease variants and information on the mechanism of action for each variant annotated.

### 2.1.3. Mode of Action and Specificity of Anti-Cancer Therapeutics

The Reactome data model allows for annotation of small molecules and antibodies used as anti-cancer therapeutics, as well as the annotation of their specific mode of action. We have annotated nine small tyrosine kinase inhibitors (TKIs) used to inhibit EGFR kinase activity in cancer \[[@B59-cancers-04-01180],[@B69-cancers-04-01180]\], as well as the recombinant antibody cetuximab \[[@B70-cancers-04-01180]\] ([Figure 3](#cancers-04-01180-f003){ref-type="fig"}a). In addition, we annotated five benzaquinoid ansamycins that inhibit the HSP90 chaperone protein that stabilizes EGFR mutant proteins \[[@B71-cancers-04-01180]\], twelve anti-FGFR TKIs \[[@B60-cancers-04-01180]\], one anti-FGFR recombinant antibody \[[@B72-cancers-04-01180]\], ten small molecules that inhibit the catalytic subunit of PI3K \[[@B61-cancers-04-01180]\], and three small molecules that inhibit AKT \[[@B61-cancers-04-01180]\] ([Table 2](#cancers-04-01180-t002){ref-type="table"}).

![Disease information presented interactively on the Reactome website. (**a**) Selecting an entity in the pathway diagram, EGFRvIII mutant in this case and opening the Reactome details pane by clicking on the yellow triangle at the bottom of the Pathway Browser page brings up a record for the selected instance. A pathway hierarchy displayed on the left hand side shows how the selected instance is related to the rest of the pathway content. (**b**) Reactome record, displayed in the details pane, provides information on the selected entity, including cross-references to other databases such as COSMIC, UniProt, GO. (**c**) Cross-reference to Disease Ontology: clicking on a disease attribute, such as "adult glioblastoma multiforme", provides a Disease Ontology (DO) identifier for this disease instance (3075) and lists all proteins in Reactome database associated with adult glioblastoma multiforme.](cancers-04-01180-g002){#cancers-04-01180-f002}

![Mode of action and specificity of anti-EGFR cancer therapeutics. (**a**) Anti-EGFR therapeutics differ in their specificity for EGFR cancer variants, as well as in their mode of action (non-covalent *vs*. covalent binding). (**b**) Classification of EGFR-binding small tyrosine kinase inhibitors (TKIs) according to spectrum and reversibility of their binding.](cancers-04-01180-g003){#cancers-04-01180-f003}

For each anti-EGFR TKI, we specify whether it associates with the EGFR catalytic domain through formation of a covalent (irreversible) bond or through a non-covalent interaction (reversible). We also specify whether a TKI is EGFR-specific or whether it can inhibit other receptor tyrosine kinases besides EGFR (EGFRplus). Each small molecule instance we annotate is associated with the Chemical Entities of Biological Interest (ChEBI) database identifier \[[@B19-cancers-04-01180]\]. On the Reactome website, a link to a corresponding ChEBI record is displayed after the name of each small molecule. Clicking on the ChEBI link associated with gefitinib ([Figure 3](#cancers-04-01180-f003){ref-type="fig"}b) directs the user to the gefitinib information in ChEBI, displaying its molecular structure and additional information not directly captured by Reactome.

EGFR cancer mutants in Reactome are classified into sets based on their sensitivity to various TKIs ([Figure 3](#cancers-04-01180-f003){ref-type="fig"}a). Ligand responsive EGFR mutants sensitive to non-covalent TKIs can be inhibited by low concentrations of non-covalent (reversible) TKIs that do not significantly affect the function of wild-type EGFR and therefore produce minimal side effects. Ligand responsive EGFR mutants resistant to non-covalent TKIs can be inhibited by covalent (irreversible) TKIs. As can be seen from the diagram ([Figure 3](#cancers-04-01180-f003){ref-type="fig"}a), concentrations of irreversible TKIs that inhibit EGFR mutants also inhibit the function of the wild-type protein, causing more severe side effects, as described in event summations. Cetuximab is used for treatment of cancers that overexpress wild-type EGFR protein, usually due to amplification of the EGFR locus \[[@B59-cancers-04-01180],[@B70-cancers-04-01180]\].

cancers-04-01180-t001_Table 1

###### 

Cancer-related disease variants published by Reactome to date. A total of \~150 cancer mutants have been published since the start of the project in December 2010.

  Disease Variant                   COSMIC Identifier(s)         Mutation Type        Disease                                                                                                                                                                                                                                                                             Reactome Pathway Name
  --------------------------------- ---------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  EGFR A289D mutant                 21685                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by EGFR in Cancer
  EGFR A289T mutant                 21686                        Missense             Glioblastoma, oligodendroglioma                                                                                                                                                                                                                                                     Signaling by EGFR in Cancer
  EGFR A289V mutant                 21687                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by EGFR in Cancer
  EGFR D770_N771insNPG mutant                                    Insertion            Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR D770_N771insNPH mutant       48920                        Insertion            Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR E746_A750del mutant          6223, 129800, 6225           Deletion             Breast, head and neck, kidney, lung, ovarian, salivary gland and thyroid cancer                                                                                                                                                                                                     Signaling by EGFR in Cancer
  EGFR E746_A750del; T790M mutant                                Deletion; Missense   Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR E746_S752delinsV mutant      18492, 18426, 12384, 85797   Deletion             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR E746_T751delinsA mutant      20845, 12678, 13549          Deletion             Head and neck, lung cancer                                                                                                                                                                                                                                                          Signaling by EGFR in Cancer
  EGFR G598V mutant                 34167, 21690                 Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by EGFR in Cancer
  EGFR G719A mutant                 6239, 13448                  Missense             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR G719C mutant                 6253, 20881                  Missense             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR G719S mutant                 6252, 13983                  Missense             Colorectal, lung cancer                                                                                                                                                                                                                                                             Signaling by EGFR in Cancer
  EGFR L747_A750delinsP mutant      13562, 12382, 12422          Deletion             Head and neck, lung cancer                                                                                                                                                                                                                                                          Signaling by EGFR in Cancer
  EGFR L747_P753delinsS mutant      13564, 12370                 Deletion             Head and neck, lung, prostate cancer                                                                                                                                                                                                                                                Signaling by EGFR in Cancer
  EGFR L747_S752del mutant          13984, 6255                  Deletion             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR L747_T751del mutant          24432, 12369, 6254, 23571    Deletion             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR L747_T751delinsP mutant      24573, 12383, 22944          Deletion             Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR L858R mutant                 6224, 12979                  Missense             Breast, lung, ovarian, stomach, thymus and thyroid cancer, mesothelioma                                                                                                                                                                                                             Signaling by EGFR in Cancer
  EGFR L858R;T790M mutant                                        Missense; Missense   Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR L861Q mutant                 6213, 13173                  Missense             Lung cancer, glioblastoma                                                                                                                                                                                                                                                           Signaling by EGFR in Cancer
  EGFR M766_A767insASV mutant                                    Insertion            Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFR R108K mutant                 21683, 34166                 Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by EGFR in Cancer
  EGFR T263P mutant                 21684                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by EGFR in Cancer
  EGFR V738_K739insKIPVAI mutant                                 Insertion            Lung cancer                                                                                                                                                                                                                                                                         Signaling by EGFR in Cancer
  EGFRvIII mutant                   21351                        Deletion             Lung cancer, glioblastoma                                                                                                                                                                                                                                                           Signaling by EGFR in Cancer
  BCR-FGFR1 fusion mutant                                        Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  CNTRL-FGFR1 fusion mutant                                      Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  CPSF6-FGFR1 fusion mutant                                      Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  CUX1-FGFR1 fusion mutant                                       Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR1 K656E mutant                35673                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by FGFR in Disease
  FGFR1 N546K mutant                19176                        Missense             Glioblastoma, hypochondroplasia                                                                                                                                                                                                                                                     Signaling by FGFR in Disease
  FGFR1 P252S mutant                                             Missense             Melanoma                                                                                                                                                                                                                                                                            Signaling by FGFR in Disease
  FGFR1 P252T mutant                12834                        Missense             Lung cancer                                                                                                                                                                                                                                                                         Signaling by FGFR in Disease
  FGFR1 R576W mutant                19177                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        Signaling by FGFR in Disease
  FGFR1OP-FGFR1 fusion mutant                                    Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR1OP2-FGFR1 fusion mutant                                   Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR1c P252R mutant                                            Missense             Pfeiffer syndrome                                                                                                                                                                                                                                                                   Signaling by FGFR in Disease
  FGFR2 K660E mutant                36909                        Missense             Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2 K660M mutant                49175                        Missense             Cervical cancer                                                                                                                                                                                                                                                                     Signaling by FGFR in Disease
  FGFR2 K660N mutant                49173                        Missense             Endometrial cancer, Crouzon syndrome                                                                                                                                                                                                                                                Signaling by FGFR in Disease
  FGFR2 L764fs\*4STOP mutant                                     Frameshift           Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2 N549H mutant                                             Missense             Crouzon syndrome                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR2 N549K mutant                36912, 36902                 Missense             Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2 S267P mutant                                             Missense             Stomach cancer, Crouzon syndrome                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR2 W290C mutant                41286                        Missense             Lung cancer, Pfeiffer syndrome                                                                                                                                                                                                                                                      Signaling by FGFR in Disease
  FGFR2b P253R mutant               49170                        Missense             Endometrial cancer, acrocephalosyndactylia                                                                                                                                                                                                                                          Signaling by FGFR in Disease
  FGFR2b S252W mutant               36903, 41289                 Missense             Endometrial, ovarian cancer, acrocephalosyndactylia, craniosynostosis                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR2b S373C mutant               36905                        Missense             Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2b Y376C mutant               36904, 41290                 Missense             Endometrial, ovarian cancer                                                                                                                                                                                                                                                         Signaling by FGFR in Disease
  FGFR2c A314D mutant               49171                        Missense             Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2c A314S mutant                                            Missense             Bone development disease                                                                                                                                                                                                                                                            Signaling by FGFR in Disease
  FGFR2c A315S mutant                                            Missense             Syndactyly                                                                                                                                                                                                                                                                          Signaling by FGFR in Disease
  FGFR2c A315T mutant               30777                        Missense             Endometrial cancer                                                                                                                                                                                                                                                                  Signaling by FGFR in Disease
  FGFR2c P253R mutant               49170                        Missense             Endometrial cancer, acrocephalosyndactylia                                                                                                                                                                                                                                          Signaling by FGFR in Disease
  FGFR2c S252W mutant               41289, 36903                 Missense             Endometrial, ovarian cancer, acrocephalosyndactylia, craniosynostosis                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR2c S372C mutant                                            Missense             Beare-Stevenson cutis gyrata syndrome                                                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR2c W290G mutant                                            Missense             Crouzon syndrome, Pfeiffer syndrome                                                                                                                                                                                                                                                 Signaling by FGFR in Disease
  FGFR2c Y375C mutant                                            Missense             Beare-Stevenson cutis gyrata syndrome                                                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR3 795fs\*139STOP mutant                                    Frameshift           Multiple myeloma, thanatophoric dysplasia                                                                                                                                                                                                                                           Signaling by FGFR in Disease
  FGFR3 A391E mutant                721                          Missense             Bladder cancer, Crouzon syndrome                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR3 G370C mutant                716, 35897                   Missense             Bladder cancer, thanatophoric dysplasia                                                                                                                                                                                                                                             Signaling by FGFR in Disease
  FGFR3 G380R mutant                24842, 24812                 Missense             Bladder cancer, multiple myeloma, achondroplasia                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR3 G382D mutant                727                          Missense             Multiple myeloma                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR3 K650E mutant                719, 35899                   Missense             Bladder, testicular cancer, multiple myeloma, thanatophoric dysplasia                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR3 K650M mutant                720, 85791                   Missense             Bladder, testicular cancer, multiple myeloma, thanatophoric dysplasia                                                                                                                                                                                                               Signaling by FGFR in Disease
  FGFR3 K650N mutant                                             Missense             Bladder, testicular cancer, hypochondroplasia                                                                                                                                                                                                                                       Signaling by FGFR in Disease
  FGFR3 K650Q mutant                726                          Missense             Bladder cancer, hypochondroplasia                                                                                                                                                                                                                                                   Signaling by FGFR in Disease
  FGFR3 K650T mutant                731                          Missense             Bladder, testicular cancer, hypochondroplasia                                                                                                                                                                                                                                       Signaling by FGFR in Disease
  FGFR3 R248C mutant                714, 35896                   Missense             Bladder cancer, multiple myeloma, thanatophoric dysplasia                                                                                                                                                                                                                           Signaling by FGFR in Disease
  FGFR3 S371C mutant                17461, 35898                 Missense             Bladder cancer, thanatophoric dysplasia                                                                                                                                                                                                                                             Signaling by FGFR in Disease
  FGFR3 Y373C mutant                718, 29428                   Missense             Bladder cancer, multiple myeloma, thanatophoric dysplasia                                                                                                                                                                                                                           Signaling by FGFR in Disease
  FGFR3b G697C mutant               24802                        Missense             Head and neck cancer                                                                                                                                                                                                                                                                Signaling by FGFR in Disease
  FGFR3b S249C mutant               715, 29427                   Missense             Bladder, cervical, head and neck, prostate cancer, thanatophoric dysplasia                                                                                                                                                                                                          Signaling by FGFR in Disease
  FGFR3c P250R mutant                                            Missense             Acrocephalosyndactylia, craniosynostosis                                                                                                                                                                                                                                            Signaling by FGFR in Disease
  FGFR4 N535D mutant                                             Missense             Rhabdomyosarcoma                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR4 N535K mutant                                             Missense             Rhabdomyosarcoma                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR4 V550E mutant                                             Missense             Rhabdomyosarcoma                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR4 V550L mutant                                             Missense             Rhabdomyosarcoma                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  FGFR4 Y367C mutant                                             Missense             Breast cancer                                                                                                                                                                                                                                                                       Signaling by FGFR in Disease
  LRRFIP1-FGFR1 fusion mutant                                    Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  MYO18A-FGFR1 fusion mutant                                     Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  TRIM24-FGFR1 fusion mutant                                     Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  ZMYM2-FGFR1 fusion mutant                                      Translocation        Myeloid leukemia                                                                                                                                                                                                                                                                    Signaling by FGFR in Disease
  IDH1 R132C mutant                 28747, 41294                 Missense             Glioblastoma                                                                                                                                                                                                                                                                        The citric acid (TCA) cycle and respiratory electron transport
  IDH1 R132H mutant                 28746, 41291                 Missense             Glioblastoma                                                                                                                                                                                                                                                                        The citric acid (TCA) cycle and respiratory electron transport
  IDH1 R132L mutant                 28750                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        The citric acid (TCA) cycle and respiratory electron transport
  IDH1 R132S mutant                 28748                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        The citric acid (TCA) cycle and respiratory electron transport
  PIK3CA E542K mutant               760, 29329                   Missense             Bladder, breast, cervical, colorectal, endometrial, esophageal, gallbladder, head and neck, kidney, liver, lung, ovarian, penis, pharynx, pituitary, skin sweat gland, stomach, thyroid cancer, glioblastoma, lymphocytic leukemia                                                  PI3K/AKT Signaling in Cancer
  PIK3CA E542Q mutant               17442                        Missense             Breast, colorectal, endometrial, lung cancer                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PIK3CA E542V mutant               762                          Missense             Breast, colorectal, endometrial, ovarian cancer                                                                                                                                                                                                                                     PI3K/AKT Signaling in Cancer
  PIK3CA E545A mutant               12458                        Missense             Breast, colorectal, endometrial, esophageal, lung, ovarian, prostate, thyroid cancer, glioblastoma, hepatoblastoma, synovial sarcoma                                                                                                                                                PI3K/AKT Signaling in Cancer
  PIK3CA E545G mutant               764                          Missense             Bladder, breast, colorectal, endometrial, head and neck, larynx, pituitary, stomach cancer, myeloid leukemia, non-Hodgkin lymphoma, retinoblastoma                                                                                                                                  PI3K/AKT Signaling in Cancer
  PIK3CA E545K mutant               763, 29328                   Missense             Bladder, breast. cervical, colorectal, endometrial, esophageal, gallbladder, head and neck, kidney, lung, ovarian, pancreatic, penis, pharynx, skin, stomach, sweat gland, thyroid cancer, melanoma, glioblastoma, medulloblastoma, myeloma, pituitary adenoma                      PI3K/AKT Signaling in Cancer
  PIK3CA E545Q mutant               27133                        Missense             Bladder, breast, colorectal, esophageal, head and neck, ovarian, thyroid cancer                                                                                                                                                                                                     PI3K/AKT Signaling in Cancer
  PIK3CA E545V mutant               144201                       Missense             Ovarian cancer                                                                                                                                                                                                                                                                      PI3K/AKT Signaling in Cancer
  PIK3CA H1047L mutant              776, 30744                   Missense             Bladder, breast, colorectal, endometrial, head and neck, liver, lung, ovarian, pharynx, thyroid cancer, glioblastoma, non-Hodgkin lymphoma, pituitary adenoma                                                                                                                       PI3K/AKT Signaling in Cancer
  PIK3CA H1047R mutant              775, 29325                   Missense             Bladder, breast, cervical, colorectal, endometrial, gallbladder, head and neck, liver, lung, ovarian, pancreatic, pharynx, prostate, stomach, thyroid cancer, glioblastoma, medulloblastoma, melanoma, meningioma, neuroectodermal tumor, non-Hodgkin lymphoma, pituitary adenoma   PI3K/AKT Signaling in Cancer
  PIK3CA H1047Y mutant              774, 29326                   Missense             Breast, colorectal, endometrial, lung, ovarian cancer, glioblastoma                                                                                                                                                                                                                 PI3K/AKT Signaling in Cancer
  PIK3CA M1043I mutant              773, 29313, 94984            Missense             Bladder, breast, cervical, colorectal, endometrial, lung, ovarian, thyroid cancer, glioblastoma                                                                                                                                                                                     PI3K/AKT Signaling in Cancer
  PIK3CA M1043T mutant              12463                        Missense             Ovarian, stomach cancer, glioblastoma                                                                                                                                                                                                                                               PI3K/AKT Signaling in Cancer
  PIK3CA M1043V mutant              12591, 30743                 Missense             Breast, colorectal, endometrial, head and neck, lung, ovarian, pharynx cancer, glioblastoma                                                                                                                                                                                         PI3K/AKT Signaling in Cancer
  PIK3CA Q546E mutant               6147                         Missense             Breast, cervical, colorectal, endometrial cancer                                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PIK3CA Q546H mutant               24712, 30740                 Missense             Cervical, colorectal, endometrial cancer                                                                                                                                                                                                                                            PI3K/AKT Signaling in Cancer
  PIK3CA Q546K mutant               766, 30738                   Missense             Breast, colorectal, endometrial, lung, ovarian, stomach cancer, lymphocytic leukemia                                                                                                                                                                                                PI3K/AKT Signaling in Cancer
  PIK3CA Q546L mutant               25041, 85754                 Missense             Breast, colorectal, gallbladder, head and neck cancer                                                                                                                                                                                                                               PI3K/AKT Signaling in Cancer
  PIK3CA Q546P mutant               767                          Missense             Breast, colorectal, endometrial, ovarian cancer, glioma                                                                                                                                                                                                                             PI3K/AKT Signaling in Cancer
  PIK3CA Q546R mutant               12459, 30739                 Missense             Breast. colorectal, endometrial, prostate, stomach cancer                                                                                                                                                                                                                           PI3K/AKT Signaling in Cancer
  PIK3CA R38C mutant                744                          Missense             Colorectal cancer                                                                                                                                                                                                                                                                   PI3K/AKT Signaling in Cancer
  PIK3CA R38G mutant                40945                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PIK3CA R38H mutant                745, 49022                   Missense             Breast, colorectal, endometrial cancer                                                                                                                                                                                                                                              PI3K/AKT Signaling in Cancer
  PIK3CA R38S mutant                87310                        Missense             Stomach cancer                                                                                                                                                                                                                                                                      PI3K/AKT Signaling in Cancer
  PIK3R1 D560H mutant               125378                       Missense             Pharynx cancer                                                                                                                                                                                                                                                                      PI3K/AKT Signaling in Cancer
  PIK3R1 D560Y mutant               335765                       Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PIK3R1 G376R mutant               35827, 132923                Missense             Endometrial cancer, glioblastoma                                                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PIK3R1 H450_E451del mutant        39296                        Deletion             Endometrial cancer, glioblastoma                                                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PIK3R1 K459del mutant             87216                        Deletion             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PIK3R1 N564D mutant               42912                        Missense             Colorectal, endometrial cancer, glioblastoma                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PIK3R1 N564K mutant               35808                        Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PIK3R1 R574_T576del mutant        87219                        Deletion             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PIK3R1 R574I mutant               85927                        Missense             Colorectal cancer                                                                                                                                                                                                                                                                   PI3K/AKT Signaling in Cancer
  PIK3R1 R574T mutant               87544                        Missense             Bladder, breast cancer                                                                                                                                                                                                                                                              PI3K/AKT Signaling in Cancer
  PIK3R1 Y463_L466del mutant        87228                        Deletion             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  AKT1 E17K mutant                  33765, 34142                 Missense             Breast, colorectal, ovarian cancer                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PTEN R130G mutant                 5219                         Missense             Endometrial, lung, ovarian cancer, glioblastoma                                                                                                                                                                                                                                     PI3K/AKT Signaling in Cancer
  PTEN R130Q mutant                 5033                         Missense             Breast, colorectal, endometrial, ovarian, thyroid cancer, glioma, histiocytoma                                                                                                                                                                                                      PI3K/AKT Signaling in Cancer
  PTEN R130L mutant                 5216                         Missense             Breast, endometrial cancer, Cowden syndrome                                                                                                                                                                                                                                         PI3K/AKT Signaling in Cancer
  PTEN C124S mutant                 5224, 5271                   Missense             Endometrial, thyroid cancer, glioblastoma                                                                                                                                                                                                                                           PI3K/AKT Signaling in Cancer
  PTEN C124R mutant                                              Missense             Thyroid adenoma, Cowden syndrome                                                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PTEN R173H mutant                 5039                         Missense             Endometrial, ovarian cancer, glioma                                                                                                                                                                                                                                                 PI3K/AKT Signaling in Cancer
  PTEN R173C mutant                 5089, 24682                  Missense             Endometrial cancer, glioblastoma, lymphocytic leukemia, melanoma                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PTEN R173P mutant                 12735                        Missense             Testicular cancer                                                                                                                                                                                                                                                                   PI3K/AKT Signaling in Cancer
  PTEN S170N mutant                 5045                         Missense             Endometrial cancer, glioblastoma                                                                                                                                                                                                                                                    PI3K/AKT Signaling in Cancer
  PTEN S170R mutant                                              Missense             Bannayan-Riley-Ruvalcaba syndrome                                                                                                                                                                                                                                                   PI3K/AKT Signaling in Cancer
  PTEN H123Y mutant                 5078                         Missense             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PTEN G129E mutant                 28917                        Missense             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PTEN G129R mutant                 5092                         Missense             Thyroid cancer, glioblastoma                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PTEN H93Y mutant                  5043                         Missense             Endometrial cancer, glioma, medulloblastoma                                                                                                                                                                                                                                         PI3K/AKT Signaling in Cancer
  PTEN H93A mutant                                               Missense             Cancer                                                                                                                                                                                                                                                                              PI3K/AKT Signaling in Cancer
  PTEN H93R mutant                  5060                         Missense             Glioblastoma, autism spectrum disorders                                                                                                                                                                                                                                             PI3K/AKT Signaling in Cancer
  PTEN H93D mutant                  5283                         Missense             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PTEN H93Q mutant                  5186                         Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PTEN R130P mutant                 5277                         Missense             Breast, endometrial, glioblastoma                                                                                                                                                                                                                                                   PI3K/AKT Signaling in Cancer
  PTEN C124F mutant                 13578                        Missense             Lung cancer                                                                                                                                                                                                                                                                         PI3K/AKT Signaling in Cancer
  PTEN C124Y mutant                 5140                         Missense             Stomach cancer                                                                                                                                                                                                                                                                      PI3K/AKT Signaling in Cancer
  PTEN S170I mutant                 5218                         Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PTEN S170G mutant                 5063                         Missense             Glioblastoma                                                                                                                                                                                                                                                                        PI3K/AKT Signaling in Cancer
  PTEN G129V mutant                 5276                         Missense             Endometrial cancer                                                                                                                                                                                                                                                                  PI3K/AKT Signaling in Cancer
  PTEN R130\* mutant                21342, 5152                  Nonsense             Cervical, colorectal, endometrial, lung, ovarian, prostate, thyroid cancer, glioblastoma, medulloblastoma, leimyosarcoma                                                                                                                                                            PI3K/AKT Signaling in Cancer
  PTEN R233\* mutant                5154, 21343                  Nonsense             Cervical, colorectal, endometrial, lung, ovarian cancer, glioblastoma, histiocytoma, lymphocytic leukemia,                                                                                                                                                                          PI3K/AKT Signaling in Cancer
  PTEN R335\* mutant                5775, 5151                   Nonsense             Head and neck, stomach cancer, glioblastoma, melanoma, Burkitt lymphoma, lymphocytic leukemia                                                                                                                                                                                       PI3K/AKT Signaling in Cancer
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Anti-cancer therapeutics published by Reactome to date. A total of 39 small molecule inhibitors and 2 recombinant antibodies have been published since the start of the project in December 2010.

  Anti-Cancer Therapeutic   Reference Molecule Identifier   Specificity                           Reactome Pathway Name
  ------------------------- ------------------------------- ------------------------------------- ------------------------------
  17-AAG                    ChEBI^a^: 64153                 HSP90                                 Signaling by EGFR in Cancer
  17-DMAG                   ChEBI:65324                     HSP90                                 Signaling by EGFR in Cancer
  Afatinib                  ChEBI:61390                     EGFR, ERBB2                           Signaling by EGFR in Cancer
  Canertinib                ChEBI:61399                     Pan-ERBB                              Signaling by EGFR in Cancer
  Cetuximab                 Recombinant antibody            EGFR                                  Signaling by EGFR in Cancer
  Erlotinib                 ChEBI:114785                    EGFR                                  Signaling by EGFR in Cancer
  Gefitinib                 ChEBI:49668                     EGFR                                  Signaling by EGFR in Cancer
  Geldanamycin              ChEBI:5292                      HSP90                                 Signaling by EGFR in Cancer
  HKI-272                   ChEBI:61390                     EGFR, ERBB2                           Signaling by EGFR in Cancer
  Herbimycin A              ChEBI:5674                      HSP90                                 Signaling by EGFR in Cancer
  Lapatinib                 ChEBI:49603                     EGFR, ERBB2                           Signaling by EGFR in Cancer
  Pelitinib                 ChEBI:38927                     EGFR                                  Signaling by EGFR in Cancer
  Vandetanib                ChEBI:49960                     EGFR, VEGFR                           Signaling by EGFR in Cancer
  WZ4002                    ChEBI:61400                     EGFR                                  Signaling by EGFR in Cancer
  IPI-504                   Pending                         HSP90                                 Signaling by EGFR in Cancer
  AZ 2171                   ChEBI:556867                    FGFR, PDGFR, VEGFR. KIT               Signaling by FGFR in Disease
  Brivanib                  ChEBI:443041                    FGFR, VEGFR                           Signaling by FGFR in Disease
  Brivanib alaninate        ChEBI:270995                    FGFR, VEGFR                           Signaling by FGFR in Disease
  Dovitinib                 ChEBI:594834                    FGFR, FLT3, VEGFR, PDGFR, KIT, CSFR   Signaling by FGFR in Disease
  E3810                     Pending                         FGFR, VEGFR                           Signaling by FGFR in Disease
  E7080                     ChEBI:816009                    FGFR VEGFR, PDGFR                     Signaling by FGFR in Disease
  Masitinib                 ChEBI:63450                     FGFR3, PDGFR, KIT                     Signaling by FGFR in Disease
  GP369                     Recombinant antibody            FGFR2b                                Signaling by FGFR in Disease
  Midostaurin               ChEBI:63452                     FGFR, FLT3, PDGFR, VEGFR, KIT, PKCA   Signaling by FGFR in Disease
  PD173074                  ChEBI:63448                     Pan-FGFR                              Signaling by FGFR in Disease
  AZD4547                   ChEBI:63453                     Pan-FGFR                              Signaling by FGFR in Disease
  BGJ398                    ChEBI:63451                     Pan-FGFR                              Signaling by FGFR in Disease
  SU5402                    ChEBI:63449                     FGFR, VEGFR                           Signaling by FGFR in Disease
  GSK1059615                Pending                         Pan-PI3K                              PI3K/AKT Signaling in Cancer
  BEZ235                    Pending                         PI3K Class I, mTOR                    PI3K/AKT Signaling in Cancer
  BGT226                    Pending                         PI3K Class I, mTOR                    PI3K/AKT Signaling in Cancer
  BKM120                    Pending                         PI3K Class I                          PI3K/AKT Signaling in Cancer
  XL765                     Pending                         PI3K Class I, mTOR                    PI3K/AKT Signaling in Cancer
  XL147                     Pending                         PI3K Class I                          PI3K/AKT Signaling in Cancer
  GDC0941                   ChEBI:65326                     PI3K Class I                          PI3K/AKT Signaling in Cancer
  PX-866                    ChEBI:65345                     PIK3CA, PIK3CD, PIK3CG                PI3K/AKT Signaling in Cancer
  LY294002                  ChEBI:65329                     Pan-PI3K                              PI3K/AKT Signaling in Cancer
  wortmannin                ChEBI:52289                     Pan-PI3K                              PI3K/AKT Signaling in Cancer
  Perifosine                ChEBI:428891                    AKT                                   PI3K/AKT Signaling in Cancer
  MK2206                    ChEBI:716367                    AKT                                   PI3K/AKT Signaling in Cancer
  Triciribine               ChEBI:65310                     AKT                                   PI3K/AKT Signaling in Cancer

2.2. Other Disease Pathways in Reactome
---------------------------------------

In addition to cancer, Reactome also collects and provides information on communicable diseases. Currently featured infection-related Reactome pathways are "HIV Infection", "Influenza Infection", "Botulinum Neurotoxicity", and "Latent Infection with Mycobacterium tuberculosis". The pathway "Signaling by FGFR in Disease" contains, besides information on FGFR in cancer, the information on FGFR mutations and their functional implication in various developmental disorders, such as Pfeiffer syndrome and Crouzon syndrome. Reactome has recently published "Abnormal Metabolism in Phenylketonuria" and "Mucopolysaccharidoses" pathways, thereby introducing metabolic genetic diseases.

2.3. Enhancing the Reactome Pathway Browser for Display of Disease Variants
---------------------------------------------------------------------------

The Reactome Pathway Browser, based upon the Systems Biology Graphical Notation (SBGN) \[[@B73-cancers-04-01180]\], permits the navigation and analysis of Reactome data, in a similar manner to Google Maps. SBGN is a standard graphical representation of biological pathway and network models. The Pathway Browser was adapted to enable display of disease variants and disease-related events involving proteins. A pathway diagram is shared between a wild-type pathway, for example "Signaling by EGFR", and the corresponding disease pathway, "Signaling by EGFR in Cancer". A disease attribute, attached to events involving cancer, instructs the browser to hide disease events when a user selects a wild-type pathway view ([Figure 4](#cancers-04-01180-f004){ref-type="fig"}a). When a user selects a disease pathway view, disease events appear in the diagram while all normal events are shaded gray. All disease events and physical entities with disease tags are outlined in red for easier visualization ([Figure 4](#cancers-04-01180-f004){ref-type="fig"}b).

![Display of wild-type and disease pathway diagrams. (**a**) A cancer disease attribute, assigned to events involved in cancer, instructs the browser to hide disease events when a user selects to view a wild-type pathway. (**b**) When a user selects to view a disease pathway, disease events appear in the wild type diagram, while all normal events are shaded. All disease events and physical entities with disease tags are outlined in red for easier visualization.](cancers-04-01180-g004){#cancers-04-01180-f004}

Physical entity and reaction nodes within the pathway diagrams are interactive. Clicking on either feature displays specific information and additional links out to external databases in the "Details" Panel, which opens by clicking on the yellow triangle at the bottom of the Pathway Browser page ([Figure 2](#cancers-04-01180-f002){ref-type="fig"}). Context sensitive menus, accessible through the right click on a selected entity, provide additional information about the physical entity in the pathway: a catalogue of other pathways in Reactome in which the selected entity participates; a list of the entities that contribute to the macromolecular complex; a catalogue of interactors of the selected entity; and the option to export a list of interactors of the selected entity. The latter two features of the context sensitive menu increase protein coverage and associated variant annotations. The Molecular Interaction Overlay (MI Overlay), accessible through "Analyze, Annotate & Upload" button of the Pathway Browser, displays proteins interacting with the manually annotated protein components of a Reactome pathway. This network overlay tool employs PSICQUIC (Proteomics Standard Initiative Common QUery InterfaCe) to apply an interactive display of interaction data from an external database such as IntAct \[[@B74-cancers-04-01180]\] into Reactome pathway diagrams. Other sources of interaction data include protein-protein and protein-drug/small molecule interactions; a user-supplied list can also be displayed. By displaying interaction data from ChEMBL, a database of bioactive drug-like molecules ([Figure 5](#cancers-04-01180-f005){ref-type="fig"}) \[[@B75-cancers-04-01180]\], the MI Overlay feature provides an opportunity to identify protein variant-drug interactions, identify novel cancer targets or off-target effects, or pharmaceuticals that can moderate perturbed reactions or pathways experimentally.

![AKT1 E17K mutant-small molecule interactions. When ChEMBL is selected as the interaction database, the MI Overlay displays small molecules from ChEMBL as interactors of AKT1 E17K variant protein of the PI3K/AKT Signaling in Cancer pathway. The nodes of the mini network are interactive; clicking the node to the left of the green arrow will link out to the Staurosporine protein kinase inhibitor record at ChEMBL.](cancers-04-01180-g005){#cancers-04-01180-f005}

2.4. Reactome Cancer-Perturbed Pathways Support Pathway Visualization and Analysis
----------------------------------------------------------------------------------

The Pathway Browser provides an intuitive and interactive pathway visualization system, promoting a variety of web-based data analyses of user-supplied experimental data. The Pathway Analysis tool provides two alternate functions to analyze lists of genes. First, in the identifier (ID) mapping mode, a user-supplied set of gene or protein identifiers can be mapped to Reactome events. Second, in the overrepresentation analysis mode, users can determine which pathways are statistically overrepresented in a gene/protein list. The Expression Analysis tool will aid with the biological interpretation of large-scale cancer genome sequencing, genomics and proteomics experiments. For example, this tool allows users to visualize expression data (or any other numeric value, e.g., differential expression) superimposed on the Reactome pathway diagram. Reactome applies an orthology-based computational algorithm to curated human data to infer pathways in 22 diverse model organisms. The Species Comparison tool allows users to visually compare and contrast human pathways with these predicted model organism pathways. As additional cancer-perturbed pathways are added to Reactome, this method of "inferred" curation will provide a platform from which to study molecular disease mechanisms across the evolutionary spectrum. Reactome data is available for downloading and manipulation by third party visualization and analysis tools, including Cytoscape, Vanted and CellDesigner \[[@B76-cancers-04-01180],[@B77-cancers-04-01180],[@B78-cancers-04-01180]\].

3. Experimental Section
=======================

Using the previously curated human EGFR pathway, which included a number of annotations for EGFR and downstream signaling by SHC1, GRB2, PLCG1 and CBL, as a template from which to extend the EGFR pathway, we imported this dataset into the Reactome Curator Tool \[[@B11-cancers-04-01180]\]. Briefly, the curator tool provides Reactome curators with all the necessary tools to access the Reactome database and annotate data in agreement with the Reactome data model. Curators identified research articles and reviews in PubMed that were relevant to the annotation of the cancer-perturbed EGFR, FGFR and PI3K/AKT pathways. Once publications had been reviewed, a list of cancer-related proteins, small molecules and macromolecular complexes was prepared. Additional queries were performed in UniProt and ChEBI to identify the reference entity proteins and small molecules, respectively that would be used to construct the reactions of the cancer-perturbed EGFR pathway. Additional attributes of a reaction were captured. For example, details of the input and output entity(s), the catalytic or regulatory protein(s), the cellular location(s) of the reactants, a textual summation describing the reaction and the supporting literature reference(s). The Disease Ontology terms that match literature references and COSMIC records for annotated cancer variants were assigned as disease attributes to physical entities and events involving these mutant proteins. Oncogenic overexpression of proteins as a consequence of gene amplification is usually not explicitly shown in pathway diagrams, but is captured in text summations that accompany cancer pathways.

4. Conclusions
==============

Reactome is a highly reliable, curated database of biological pathways. Through our website, we provide access to pathway and network data analysis tools for visualizing pathway data and interpreting experimental data sets. All Reactome data and software is openly available with no licensing required.

In view of the potential applicability of pathway and network analyses to identify and characterize novel cancer targets, Reactome has integrated and expanded the pathway gene product-function annotation and pathway curation to promote comprehensive and effective characterization of cancer targets, their related relationships and pathways. Our curation efforts thus far have focused on the EGFR pathway (including the EGFR, ERBB2, ERBB3, ERBB4 receptors), FGFR and PI3K-AKT signaling and their downstream effector genes. Reactome curators will enhance our curation of other cancer-perturbed pathways, such as apoptosis, cell cycle checkpoints, and other signaling pathways, including BMP, PDGF, NOTCH, VEGF, WNT, Rho-GTPase, and TGF-beta. Furthermore, as the Ontario Institute for Cancer Research and its partners in the International Cancer Genome Consortium (ICGC) \[[@B79-cancers-04-01180],[@B80-cancers-04-01180]\] sequence various tumor genomes, new cancer-related candidate pathways will be identified and curated into Reactome. Existing Reactome pathways are updated on a regular basis, and additional cancer variants and anti-cancer drugs implicated in EGFR, FGFR and PI3K/AKT pathways will be included as information on their function becomes available.

Reactome is not the only pathway database to curate pathway data relevant to cancer and disease. Cancer-perturbed signaling pathways can be found in KEGG, Panther, MetaCyc, and NCI-PID \[[@B81-cancers-04-01180],[@B82-cancers-04-01180],[@B83-cancers-04-01180],[@B84-cancers-04-01180]\]. The Reactome data model, however, provides a more detailed framework for the curation of the knowledge relevant to cancer-related pathways, a visualization environment to display pathway data, and a suite of analysis tools for the interpretation of experimental cancer data sets.

A number of other bioinformatics databases such as Mouse Genome Informatics (MGI) \[[@B85-cancers-04-01180]\] and Comparative Toxicogenomics Database (CTD) \[[@B86-cancers-04-01180]\] have established disease curation pipelines, employing OMIM. OMIM is a detail-orientated database of disease annotation, widely used by the clinical community, but it lacks the structure and features of an ontology that would otherwise make it a perfect data source to systematically reference disease. Curation of human disease requires an establishment of a widely accessible and structured vocabulary (or ontology) that consists of knowledge that is familiar to Reactome's end user, flexible to future Reactome annotation updates, and open to semantic reasoning. One such ontology is the Disease Ontology. Reactome will continue to work with the research community to support the development and continuous improvement of human disease ontologies and will link out to the relevant cancer and disease-related databases, to advance our own annotation consistency. In future versions of Reactome, we may also cross-reference NCIt \[[@B68-cancers-04-01180]\] directly for cancer-related physical entities and events. The Disease Ontology does provide NCIt identifiers when possible, but disease terms captured by the Disease Ontology and NCIt do not completely overlap. Cross-referencing different ontologies will make our disease annotations more comprehensive and stable. Since some amount of overlap exists between disease terms in any disease ontology, the overlap is reflected in our current annotation of disease attributes. This is not ideal and we are developing guidelines to standardize the use of disease terms in Reactome. As far as anti-cancer therapeutics are concerned, we do not capture their approval for clinical use other than in text summations, as this is outside the scope of Reactome project. However, cross-referencing a drug database, such as PharmaGKB \[[@B87-cancers-04-01180]\] would provide Reactome users with easy access to clinically relevant drug information, and is currently under our consideration.

We are working on further improvements to the Reactome pathway browser to produce more compact images and to be able to share one diagram between the wild-type pathway and several disease pathways with different etiologies. Furthermore, we are making additions to the Molecular Interaction Overlay to promote visual linkages between pathway entities and disease annotations, such as OMIM. Network-based methods have been used extensively in genomic and proteomic studies to analyze challenging and complex datasets. Reactome provides the Functional Interaction (FI) network plug-in for Cytoscape, which can identify network patterns related to diseases, including cancer \[[@B88-cancers-04-01180]\]. Future expansion of the FI network with interactions based upon Reactome cancer-related pathways should significantly improve coverage, enhance the functionality of the analysis, and enrich the functional annotations supported by the FI network plug-in. Reactome will continue to develop novel and useful technologies for the querying, visualization and analysis of experimental datasets, in the context of not only normal but also disease pathways.
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